华北制药注射用盐酸万古霉素获得药品注册证书

Core Viewpoint - North China Pharmaceutical has received approval from the National Medical Products Administration for the injection of Vancomycin Hydrochloride (0.5g), with a validity period until August 25, 2030 [1] Group 1: Product Information - Vancomycin Hydrochloride primarily exerts its bactericidal effect by inhibiting the biosynthesis of the bacterial cell wall [1] - The drug can alter the permeability of bacterial cell membranes and RNA synthesis [1] - It is suitable for intravenous infusion for infections caused by Methicillin-resistant Staphylococcus aureus and other bacteria, and can be taken orally for antibiotic-associated pseudomembranous colitis caused by Clostridium difficile, as well as Staphylococcal enterocolitis [1]